$Hims & Hers Health Inc.(HIMS)$ HIMS is the most underrated play in the GLP-1 and longevity space. While the market still sees it as a hair loss and ED brand, it’s the only fully digital DTC model in prescription healthcare – scalable, trusted, and built for long-term disruption. They already have a small piece of the GLP-1 market, but the real upside comes as costs drop and generics enter. What almost nobody sees yet: HIMS is quietly positioning for the next wave – peptides like BPC-157, TB500, MOTS-c. This is the Shopify of prescription meds, setting up to ride the megatrends of metabolic health and anti-aging. Founder-led, profitable growth, low float – and still massively under the radar.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments